[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
December 12, 2001

Cardiovascular Events and COX-2 Inhibitors—Reply

Author Affiliations

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;286(22):2808-2813. doi:10.1001/jama.286.22.2808

In Reply: The letter received by Dr Sperber was sent to health care providers following the numerous requests for information Merck & Co received after the publication and ensuing media reports of the article by Mukherjee et al.1 The letter we sent included selected safety information and the full text copy of the prescribing information for Vioxx (rofecoxib). In addition, Merck did send a letter to the editor (of JAMA) to express our views and recently published an article2 that provided a pooled analysis of the cardiovascular safety data for rofecoxib.